摘要
目的 :评价 AFP、CEA、CA12 5在卵巢癌诊断和监测中的应用价值。方法 :应用化学发光免疫方法检测 47例正常妇女 ,6 2例卵巢良性肿瘤 ,12例卵巢巧克力囊肿 ,41例卵巢恶性肿瘤患者血清 AFP、CEA、CA12 5值并进行比较分析。结果 :卵巢恶性肿瘤患者 AFP、CEA、CA12 5阳性率分别为 9.7%、2 6 .8%和 82 .9% ,显著高于卵巢良性肿瘤和正常妇女。在绝大多数正常妇女和卵巢良性肿瘤中 ,AFP、CEA、CA12 5在参考值范围内 ,卵巢巧克力囊肿 CA 12 5有一定程度升高。在卵巢恶性肿瘤中 ,晚期患者血清 CA12 5浓度和阳性率都显著高于早期患者。结论 :AFP、CEA、CA12 5联合应用对于卵巢癌的诊断和监别诊断及提高总的异常检出率具有价值。
Objective:To evaluate the clinical use of AFP,CEA,CA125 in diagnosis and monitoring the course of patients with ovarian tumors.Methods:Serum levels of AFP,CEA,CA125 were measured by chemiluminescence immunoassay (CLIA) in 47 healthy women,62 patients with benign ovarian tumors,12 patients with ovarian chocolate cyst,and 41 patients with ovarian carcinoma.Results:The serum AFP,CEA and CA125 positive rate were 9.7%,26.8% and 82.5% in ovarian carcinoma.The combination of AFP,CEA and CA125 assays was more sensitive,the total positive rate was 95.1%.AFP,CEA and CA125 levels were within normal range among most healthy women and patients with benign tumors. Sometimes CA125 level was high in patients with ovarian chocolate cyst.The serum levels and positive rate of CA125 in patients with Ⅲ,Ⅳ FIGO stages varian carcinoma were more higher than Ⅰ,Ⅱ stages. Conclusion:Combined measurement of AFP,CEA with CA125 was useful for the differential diagnosis and achieving higher positivity in patients with ovarian carcinoma.
出处
《肿瘤研究与临床》
CAS
2001年第1期37-39,共3页
Cancer Research and Clinic
关键词
卵巢肿瘤
甲胎蛋白
癌胚抗原
肿瘤相关
抗原
Ovarian neoplasma
Alpha fetoprotein
Carcinoembryonic antigen
Tumor-assaciated
Antigen
